RNA
NASDAQ HealthcareAvidity Biosciences, Inc. - Common Stock
Biotechnology
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
�� 市场数据
| 价格 | $14.41 |
|---|---|
| 成交量 | 632,784 |
| 市值 | 223.57M |
| RSI（14日） | 61.3 |
| 52周最高 | $16.77 |
| 52周最低 | $11.95 |
| Forward P/E | -3.57 |
| Price / Book | -3.57 |
🎯 投资策略评分
RNA 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (71/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🐋 Institutional Whale (4/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
在文本中查找 RNA in your text
粘贴任何文章、记录或帖子 — 工具将提取 RNA 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.